Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 270-281

  Fremder, Ella ^a   Munster, Michal ^a   Aharon, Anat ^b   Miller, Valeria ^a   Gingis Velitski, Svetlana ^a   Voloshin, Tali ^a   Alishekevitz, Dror ^a   Bril, Rotem ^a   Scherer, Stefan J ^c   Loven, David ^d   Brenner, Benjamin ^b   Shaked, Yuval ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Thrombosis and Homeostasis Unit Rambam Health Care Campus   (Israel)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d HAEMEK MEDICAL CENTER   (Israel)

Author keywords

angiogenesis; bone marrow derived cells; chemotherapy; microparticles

Indexed keywords

MUCIN 1; OSTEOPONTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL ACTIVITY; CELL COUNT; CELL FUNCTION; CELL HOMING; CELL INFILTRATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MEMBRANE MICROPARTICLE; MOLECULAR DYNAMICS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEM CELL MOBILIZATION; TUMOR CELL; WILD TYPE;

ANGIOGENESIS; BONE MARROW DERIVED CELLS; CHEMOTHERAPY; MICROPARTICLES;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL-DERIVED MICROPARTICLES; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; PACLITAXEL;

EID: 84900019025     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28678     Document Type: Article

References (49)

1. Shaked Y, Voest EE,. Bone marrow derived cells in tumor angiogenesis and growth: Are they the good, the bad or the evil? Biochim Biophys Acta 2009; 1796: 1-4.
2. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells. Nat Biotechnol 2007; 25: 911-20.
3. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12: 557-67.
4. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124: 175-89.
5. Petit I, Jin D, Rafii S,. The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28: 299-307.
6. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 2008; 105: 6620-5.
7. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313: 1785-7.
8. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14: 263-73.
9. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-26.
10. Kim JJ, Tannock IF,. Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer 2005; 5: 516-25.
11. Caby MP, Lankar D, Vincendeau-Scherrer C, et al. Exosomal-like vesicles are present in human blood plasma. Int Immunol 2005; 17: 879-87.
12. Piccin A, Murphy WG, Smith OP,. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 2007; 21: 157-71.
13. Toth B, Lok CA, Boing A, et al. Microparticles and exosomes: Impact on normal and complicated pregnancy. Am J Reprod Immunol 2007; 58: 389-402.
14. Mause SF, Weber C,. Microparticles: Protagonists of a novel communication network for intercellular information exchange. Circ Res 2010; 107: 1047-57.
15. Essayagh S, Xuereb JM, Terrisse AD, et al. Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thromb Haemost 2007; 98: 831-7.
16. Mack M, Kleinschmidt A, Bruhl H, et al. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: A mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 2000; 6: 769-75.
17. Simak J, Gelderman MP,. Cell membrane microparticles in blood and blood products: Potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006; 20: 1-26.
18. Mostefai HA, Andriantsitohaina R, Martinez MC,. Plasma membrane microparticles in angiogenesis: Role in ischemic diseases and in cancer. Physiol Res 2008; 57: 311-20.
19. Al Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10: 619-24.
20. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18: 883-91.
21. Ghosh AK, Secreto CR, Knox TR, et al. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010; 115: 1755-64.
22. Al Nedawi K, Meehan B, Rak J,. Microvesicles: Messengers and mediators of tumor progression. Cell Cycle 2009; 8: 2014-8.
23. Cahan MA, Walter KA, Colvin OM, Brem H,. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994; 33: 441-4.
24. Liang WC, Wu X, Peale FV, et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-61.
25. Rejiba S, Bigand C, Parmentier C, et al. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 2009; 11: 637-50.
26. Guo J, Zhou AW, Fu YC, et al. Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. Acta Pharmacol Sin 2006; 27: 1375-81.
27. Sadeghi-Aliabadi H, Minaiyan M, Dabestan A,. Cytotoxic evaluation of doxorubicin in combination with simvastatin against human cancer cells. Res Pharm Sci 2010; 5: 127-33.
28. Kevans D, Gorman S, Tosetto M, et al. Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer. J Gastrointest Cancer 2012; 43: 305-13.
29. Boilard E, Nigrovic PA, Larabee K, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580-3.
30. Gingis-Velitski S, Loven D, et al. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Res 2011; 71: 6986-96.
31. Adini A, Fainaru O, Udagawa T, et al. Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods 2009; 342: 78-81.
32. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-40.
33. Thomas GM, Panicot-Dubois L, Lacroix R, et al. Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 2009; 206: 1913-27.
34. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994-1005.
35. Shaked Y, Kerbel RS,. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007; 67: 7055-8.
36. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7: 101-11.
37. Lu KV, Chang JP, Parachoniak CA, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
38. Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010; 120: 694-705.
39. Aftab DT, McDonald DM,. MET and VEGF: Synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol 2011; 13: 703-9.
40. Pilzer D, Gasser O, Moskovich O, et al. Emission of membrane vesicles: Roles in complement resistance, immunity and cancer. Springer Semin Immunopathol 2005; 27: 375-87.
41. Baj-Krzyworzeka M, Majka M, Pratico D, et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002; 30: 450-9.
42. Ma J, Cai W, Zhang Y, et al. Innate immune cell-derived microparticles facilitate hepatocarcinoma metastasis by transferring integrin alpha(M)beta(2) to tumor cells. J Immunol 2013; 191: 3453-61.
43. Janowska-Wieczorek A, Majka M, Kijowski J, et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001; 98: 3143-9.
44. Shaked Y, Tang T, Woloszynek J, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 2009; 69: 7524-8.
45. Carmi Y, Dotan S, Rider P, et al. The role of IL-1beta in the early tumor cell-induced angiogenic response. J Immunol 2013; 190: 3500-9.
46. Wang KX, Denhardt DT,. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19: 333-45.
47. He B, Mirza M, Weber GF,. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006; 25: 2192-202.
48. Mirza M, Shaughnessy E, Hurley JK, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008; 122: 889-97.
49. Shree T, Olson OC, Elie BT, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25: 2465-79.